220 related articles for article (PubMed ID: 2417056)
1. Prostatic carcinoma metastatic to bone: sensitivity and specificity of prostate-specific antigen and prostatic acid phosphatase in decalcified material.
Shah NT; Tuttle SE; Strobel SL; Gandhi L
J Surg Oncol; 1985 Aug; 29(4):265-8. PubMed ID: 2417056
[TBL] [Abstract][Full Text] [Related]
2. Urethral metastasis from prostatic carcinoma as diagnosed by immunoperoxidase technique using prostate-specific antigen and prostate-specific acid phosphatase.
Koh E; Sekii K; Namiki M; Fujioka H; Onoue K; Sakurai M; Sonoda T
Eur Urol; 1987; 13(1-2):142-4. PubMed ID: 2438138
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical demonstration of tumor-associated antigens in prostatic carcinomas of various histological differentiations.
Friedmann W; Steffens J; Lobeck H; Blümcke S; Nagel R
Eur Urol; 1985; 11(1):52-6. PubMed ID: 2580711
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical diagnosis of the metastasizing prostatic carcinoma.
Steffens J; Friedmann W; Lobeck H
Eur Urol; 1985; 11(2):91-4. PubMed ID: 2408895
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical localization of prostate-specific acid phosphatase and prostate-specific antigen in stage A2 adenocarcinoma of the prostate: prognostic implications.
Epstein JI; Eggleston JC
Hum Pathol; 1984 Sep; 15(9):853-9. PubMed ID: 6381284
[TBL] [Abstract][Full Text] [Related]
6. [Immunohistochemical diagnosis of metastasizing prostatic carcinomas].
Friedmann W; Steffens J; Lobeck H
Onkologie; 1984 Dec; 7(6):337-41. PubMed ID: 6084838
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease.
Buamah PK; Johnson P; Skillen AW
Br J Urol; 1988 Dec; 62(6):581-3. PubMed ID: 2464396
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of commercial immunoperoxidase kits for prostatic specific antigen and prostatic specific acid phosphatase.
Svanholm H
Acta Pathol Microbiol Immunol Scand A; 1986 Jan; 94(1):7-12. PubMed ID: 2421532
[TBL] [Abstract][Full Text] [Related]
9. The relation of prostatic acid phosphatase and prostate specific antigen with tumour grade in prostatic adenocarcinoma: an immunohistochemical study.
Ersev A; Ersev D; Turkeri L; Ilker Y; Simsek F; Kullu S; Akdas A
Prog Clin Biol Res; 1990; 357():129-34. PubMed ID: 1699237
[TBL] [Abstract][Full Text] [Related]
10. Epididymal metastasis from prostatic adenocarcinoma mimicking adenomatoid tumor.
Rizk CC; Scholes J; Chen SK; Ward J; Romas NA
Urology; 1990 Dec; 36(6):526-30. PubMed ID: 1701066
[TBL] [Abstract][Full Text] [Related]
11. Immunoperoxidase localization of prostate-specific antigen.
Stein BS; Vangore S; Petersen RO; Kendall AR
Am J Surg Pathol; 1982 Sep; 6(6):553-7. PubMed ID: 6183983
[TBL] [Abstract][Full Text] [Related]
12. Immunoperoxidase localization of prostatic antigens. Comparison of primary and metastatic sites.
Stein BS; Vangore S; Petersen RO
Urology; 1984 Aug; 24(2):146-52. PubMed ID: 6205496
[TBL] [Abstract][Full Text] [Related]
13. [Role of prostate-specific antigen in prostatic carcinoma. Validity of an integrated methodologic approach and morpho-biological correlations].
Tomasino RM; Lo Bianco A; Cacciatore M; Pavone C; Carreca I; Morello V; Salvato M; Florena AM; Pavone-Macaluso M
Pathologica; 1989; 81(1072):109-26. PubMed ID: 2475847
[TBL] [Abstract][Full Text] [Related]
14. NKX3.1 as a marker of prostatic origin in metastatic tumors.
Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
[TBL] [Abstract][Full Text] [Related]
15. Prostatic origin of metastases: immunoperoxidase localization of prostate-specific antigen.
Ghazizadeh M; Kagawa S; Maebayashi K; Izumi K; Kurokawa K
Urol Int; 1984; 39(1):9-12. PubMed ID: 6203202
[TBL] [Abstract][Full Text] [Related]
16. Systematic association of PAP and PSA determinations to bone scintigraphy in prostatic cancer.
Fincker F; Sauvan R; Pasquier J
Am J Clin Oncol; 1988; 11 Suppl 2():S68-70. PubMed ID: 2468277
[TBL] [Abstract][Full Text] [Related]
17. Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate.
Ellis DW; Leffers S; Davies JS; Ng AB
Am J Clin Pathol; 1984 Mar; 81(3):279-84. PubMed ID: 6199966
[TBL] [Abstract][Full Text] [Related]
18. Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens.
Gallee MP; Visser-de Jong E; van der Korput JA; van der Kwast TH; ten Kate FJ; Schroeder FH; Trapman J
Urol Res; 1990; 18(3):181-7. PubMed ID: 1697709
[TBL] [Abstract][Full Text] [Related]
19. Significance of PSA and PAP in patients with or without prostatic cancer.
Caty A; Gosselin P; Cazin JL; Dehaut JM; Adenis L
Am J Clin Oncol; 1988; 11 Suppl 2():S63-4. PubMed ID: 2468275
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen as a marker of adenocarcinoma of prostate.
Kellokumpu-Lehtinen P; Nurmi M; Koskinen P; Irjala K
Urol Res; 1989; 17(4):245-9. PubMed ID: 2475959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
